API
< Back to all clusters
[BUSINESS] · South Korea · 2 sources

started · updated

Celltrion Pharm launches Yuflyma 40mg PFS-S in South Korea

Celltrion Pharm has launched the 40mg safety-device pre-filled syringe (PFS-S) version of its autoimmune disease treatment, Yuflyma (adalimumab), in the South Korean market. The product was officially listed under the national health insurance coverage starting November 1.

The PFS-S formulation includes a safety mechanism designed to cover the needle after injection, which aims to reduce needle exposure and assist medical professionals with safer handling. The price for a single dose is set at 220,390 KRW, which the company stated is the lowest price among equivalent 40mg products covered by health insurance in the country.

This launch expands the Yuflyma product lineup beyond the existing pen-type delivery method. Celltrion Pharm also announced plans to release a 20mg PFS version next year, which would allow the company to offer a full range of dosages and formulations comparable to original brand-name drugs.

Entities

Celltrion Pharm · South Korea · Yuflyma